Den Europæiske Union - dansk - EMA (European Medicines Agency)

sandoz gmbh - epoetin alfa - anemia; kidney failure, chronic - antianemiske præparater - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. hjerte-kar-status, præ-eksisterende anæmi ved start af kemoterapi).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemiske præparater - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. behandling af anæmi og til nedsættelse af transfusion hos voksne patienter, der modtager kemoterapi for massive tumorer, malignt lymfom eller myelomatose, og ved risiko for transfusion som vurderet af patientens almene status (e. hjerte-kar-status, præ-eksisterende anæmi ved start af kemoterapi).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - alle andre terapeutiske produkter - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - alle andre terapeutiske produkter - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - eftrenonacog alfa - hæmofili b - k-vitamin og andre hemostatics, blod koagulation faktorer - behandling og profylakse af blødning hos patienter med hæmofili b (medfødt faktor ix-mangel).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bpl bioproducts laboratory gmbh - human koagulationsfaktor x - faktor x-mangel - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex er indiceret til behandling og profylakse af blødninger episoder og for perioperative management hos patienter med arvelig faktor x mangel. coagadex er angivet i alle aldersgrupper.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

omrix biopharmaceuticals n. v. - humant fibrinogen, human thrombin - hæmostase - lokale hemostatics - støttende behandling i voksenoperation, hvor standard kirurgiske teknikker er utilstrækkelige (se afsnit 5. 1):- for forbedring af haemostasis.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - deferoxaminmesilat - pulver til injektions-/infusionsvæske, opløsning - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

novartis healthcare a/s - deferoxaminmesilat - pulver til injektions-/infusionsvæske, opløsning - 500 mg